Improvement of inflammatory responses associated with NF-κB pathway in kidneys from diabetic rats

被引:79
作者
Chen, L. [1 ]
Zhang, J. [1 ]
Zhang, Y. [1 ]
Wang, Y. [1 ]
Wang, B. [1 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Endocrinol, Union Hosp, Tongji Med Coll, Wuhan 4300022, Peoples R China
关键词
procetofen; NF-kappa B; kidney; diabetes;
D O I
10.1007/s00011-006-6190-z
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: The effects of fenofibrate on the kidneys of diabetic rats were investigated by measuring the inflammatory responses associated with transcription factor nuclear factor kappa-B (NF-kappa B) pathway. Methods: Male Wistar rats were randomly divided into 3 groups: normal control, diabetes control and diabetes + fenofibrate (10 in each group). The expression of NF-kappa B p65, plasminogen activator inhibitor-1 (PAI-1), and intercellular adhesion molecule-1 (ICAM-1) in renal cortex was detected by Western blot, RT-PCR, and immunohistochemistry, respectively. Blood lipid profiles, glucose, and urine albumin were measured as well. Results: The expression of NF-kappa B, p65, PAI-1, and ICAM-1 was significantly higher in the diabetes control than those in the normal control, and treatment with fenofibrate inhibited the increased expression of these factors in kidneys by 48.18%, 35.04%, and 26.41%, respectively when compared with the diabetes control, although they were still higher in diabetes + fenofibrate than those in the normal control. Correspondingly, the profiles of lipid were significantly elevated in the diabetes control compared with the normal control, and decreased significantly in diabetes + fenofibrate. Conclusions: Fenofibrate exhibited a downregulating effect on the NF-kappa B pathway in diabetic kidneys, implying that fenofibrate could be a potential treatment for diabetic nephropathy.
引用
收藏
页码:199 / 204
页数:6
相关论文
共 31 条
[1]   Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment [J].
Ceriello, A ;
Quagliaro, L ;
Piconi, L ;
Assaloni, R ;
Da Ros, R ;
Maier, A ;
Esposito, K ;
Giugliano, D .
DIABETES, 2004, 53 (03) :701-710
[2]   Interaction of native and modified low-density lipoproteins with extracellular matrix [J].
Chait, A ;
Wight, TN .
CURRENT OPINION IN LIPIDOLOGY, 2000, 11 (05) :457-463
[3]  
Critchley JAJH, 2002, CHINESE MED J-PEKING, V115, P129
[4]   Kidney involvement in a nongenetic rat model of type 2 diabetes [J].
Danda, RS ;
Habiba, NM ;
Rincon-Choles, H ;
Bhandari, BK ;
Barnes, JL ;
Abboud, HE ;
Pergola, PE .
KIDNEY INTERNATIONAL, 2005, 68 (06) :2562-2571
[5]   Plasminogen activator inhibitor-1 and the kidney [J].
Eddy, AA .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 283 (02) :F209-F220
[6]   Renal fibrosis: not just PAI-1 in the sky [J].
Fogo, AB .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :326-328
[7]   Leukocyte recruitment and vascular injury in diabetic nephropathy [J].
Galkina, Elena ;
Ley, Klaus .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (02) :368-377
[8]   Transcription factor-κB (NF-κB) and renal disease [J].
Guijarro, C ;
Egido, J .
KIDNEY INTERNATIONAL, 2001, 59 (02) :415-424
[9]  
Ha HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134894
[10]  
Jialin Y., 2003, ACTA LAB ANIM SCI SI, V11, P138